According to the CDC, frequent consumption of sugary drinks is linked to adverse health outcomes that include obesity, type 2 ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

This year’s report shows risk factors on the rise, enduring racial and geographic gaps, and clues to the global picture, too.

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...